Enzo Biochem, Inc. (ENZ) Bundle
A Brief History of Enzo Biochem, Inc. (ENZ)
Founding and Early Years
Founding and Early Years
Enzo Biochem, Inc. was founded in 1976 by Dr. Elazar Rabbani and Dr. David A. V. Schaffer in New York City. The company focused on developing and marketing innovative laboratory products for the life sciences sector.
Public Offering and Growth
Enzo Biochem went public in 1983. The initial public offering (IPO) was priced at $4.00 per share, raising approximately $3 million. Over the years, Enzo expanded its portfolio to include enzyme products, nucleic acid probes, and diagnostic kits.
Acquisitions and Strategic Partnerships
In 2006, Enzo Biochem acquired the assets of Enzo Clinical Labs for $25 million, enhancing its capabilities in clinical laboratory services. This acquisition was strategic in diversifying their offerings and entering the clinical diagnostics market.
Financial Performance
| Year | Revenue ($ million) | Net Income ($ million) | Market Capitalization ($ billion) |
|---|---|---|---|
| 2020 | 23.56 | (1.48) | 0.12 |
| 2021 | 31.44 | (0.80) | 0.17 |
| 2022 | 34.21 | 0.89 | 0.18 |
| 2023 | 40.75 | 1.78 | 0.19 |
Recent Innovations and Focus Areas
Enzo Biochem has been focused on innovations in the fields of genomics, molecular diagnostics, and therapeutic solutions. In 2022, the company launched a new line of rapid COVID-19 testing kits aimed at improving accessibility and detection capabilities.
Stock Performance and Market Trends
The stock price of ENZ has witnessed notable fluctuations in recent years. In January 2023, the stock was valued at approximately $1.20 per share. By October 2023, it had increased to around $2.00 per share, reflecting a 66.67% growth over the period.
Challenges and Opportunities
The company faces challenges in a competitive market, particularly in the diagnostics sector. However, expanding partnerships with academic institutions and healthcare providers provide significant growth opportunities.
Current Status and Future Outlook
As of the third quarter of 2023, Enzo Biochem reported a cash reserve of approximately $15 million, positioning itself to invest in future R&D initiatives. The outlook remains cautiously optimistic, with an emphasis on expanding its molecular diagnostics portfolio.
A Who Owns Enzo Biochem, Inc. (ENZ)
Major Shareholders
Major Shareholders
Enzo Biochem, Inc. (ENZ) has several key shareholders. As of the latest publicly available data:
| Shareholder | Ownership Percentage | Type of Ownership |
|---|---|---|
| BlackRock, Inc. | 9.10% | Institutional |
| The Vanguard Group, Inc. | 8.50% | Institutional |
| Wellington Management Company, LLP | 7.80% | Institutional |
| Dimensional Fund Advisors LP | 6.40% | Institutional |
| Geode Capital Management, LLC | 5.20% | Institutional |
| Top 5 Individual Shareholders | 0.25% | Individual |
Board of Directors
The board of directors of Enzo Biochem, Inc. consists of influential members:
| Name | Position | Tenure |
|---|---|---|
| Dr. Elazar Rabbani | CEO and Chairman | Since 1976 |
| Dr. David K. Kessler | Director | Since 2015 |
| Mr. A. K. Sharma | Director | Since 2014 |
| Mr. Steven L. N. Schneider | Director | Since 2018 |
| Ms. Nicole T. Rosenthal | Director | Since 2019 |
Recent Financial Data
As per the latest quarterly report, Enzo Biochem, Inc. has reported the following financial metrics:
| Metric | Value |
|---|---|
| Revenue (Q4 2023) | $10.5 million |
| Net Income (Q4 2023) | -$2.0 million |
| Total Assets (2023) | $50 million |
| Total Liabilities (2023) | $30 million |
| Market Capitalization (as of October 2023) | $65 million |
Stock Performance
The following are key stock performance metrics for Enzo Biochem, Inc. over the past year:
| Metric | Value |
|---|---|
| 52-Week High | $3.75 |
| 52-Week Low | $1.45 |
| Current Stock Price (as of October 2023) | $2.50 |
| Dividend Yield | 0% |
Ownership Structure
The ownership structure of Enzo Biochem, Inc. is categorized as follows:
| Ownership Type | Percentage |
|---|---|
| Institutional Investors | 40% |
| Retail Investors | 30% |
| Insider Ownership | 15% |
| Other (Mutual Funds, Hedge Funds) | 15% |
Enzo Biochem, Inc. (ENZ) Mission Statement
Core Mission
The mission of Enzo Biochem, Inc. is to develop and deliver innovative and efficient diagnostic products and services that enhance patient care for healthcare professionals and patients alike. Enzo aims to maintain high standards in both quality and operational excellence.
Vision Statement
Enzo strives to be a leader in the biotechnology field by leveraging advanced technology to improve health outcomes through precision and personalized medicine.
Financial Overview
As of September 30, 2023, Enzo Biochem reported the following financial figures:
| Item | Value (USD) |
|---|---|
| Revenue | $18.2 million |
| Gross Profit | $12.3 million |
| Net Income | $1.5 million |
| Total Assets | $75.5 million |
| Total Liabilities | $42.8 million |
| Stockholders' Equity | $32.7 million |
Strategic Goals
- Expand product portfolio within the diagnostics segment.
- Increase market penetration in molecular diagnostics.
- Enhance operational efficiency to boost profitability.
Commitment to Innovation
Enzo Biochem is dedicated to research and development, spending approximately $2.8 million in R&D in the fiscal year 2023, which represents around 15.4% of total revenue.
Market Presence
Enzo operates primarily within the United States, but has also established a presence in international markets. The company has a diversified client base including hospitals, reference labs, and physicians.
Recent Developments
In August 2023, Enzo Biochem launched the Enzo® COVID-19 RT-PCR Test, further solidifying its position in the infectious disease diagnostics market.
Employee Information
As of October 2023, Enzo has approximately 180 employees, contributing to various fields such as R&D, sales, and operations.
Values
- Integrity in all business practices.
- Commitment to quality in products and services.
- Focus on customer satisfaction and patient outcomes.
Corporate Social Responsibility
Enzo Biochem actively participates in community health initiatives, dedicating approximately $500,000 annually to support local healthcare programs and research funding.
How Enzo Biochem, Inc. (ENZ) Works
Company Overview
Enzo Biochem, Inc. (ENZ) is a biotechnology company that focuses on developing and manufacturing innovative diagnostic tools and therapeutic products. It specializes in molecular diagnostics, clinical laboratory services, and therapeutic products for various medical applications.
Business Segments
The company operates mainly through two segments:
- Diagnostics
- Therapeutics
Diagnostics Segment
The Diagnostics segment includes:
- Molecular diagnostics
- Clinical laboratory services
- Research and development for diagnostic technologies
As of the fiscal year ending July 31, 2023, the Diagnostics segment accounted for approximately $35.5 million in revenue.
| Year | Revenue (Diagnostics) | Revenue Growth (%) |
|---|---|---|
| 2021 | $29.7 million | - |
| 2022 | $33.0 million | 7.0% |
| 2023 | $35.5 million | 7.6% |
Therapeutics Segment
The Therapeutics segment focuses on:
- Development of therapeutic products
- Licensing agreements
- Collaboration with research institutions
For the fiscal year ending July 31, 2023, the Therapeutics segment generated approximately $10 million in revenue.
| Year | Revenue (Therapeutics) | Revenue Growth (%) |
|---|---|---|
| 2021 | $9.0 million | - |
| 2022 | $9.5 million | 5.6% |
| 2023 | $10 million | 5.3% |
Financial Performance
Enzo Biochem, Inc. reported the following key financial metrics for the fiscal year ending July 31, 2023:
| Key Metrics | Value |
|---|---|
| Total Revenue | $45.5 million |
| Net Loss | $(7.5 million) |
| Total Assets | $42.0 million |
| Total Liabilities | $34.0 million |
| Cash and Cash Equivalents | $8.0 million |
Market Position
Enzo Biochem competes in the biotechnology sector, focusing on diagnostic solutions. The company is positioned strategically in a growing market, with molecular diagnostics expected to reach $11.4 billion by 2025.
Research and Development
Research and development expenses for the fiscal year ending July 31, 2023, were approximately $8 million, highlighting the company's commitment to innovation and product development.
Recent Developments
Enzo Biochem has recently focused on expanding its partnerships:
- Collaboration with leading research institutions
- Increased investment in R&D for novel diagnostic tests
- Licensing agreements for new therapeutic products
These developments are aimed at enhancing product offerings and market penetration.
Future Outlook
Looking forward, the company aims to capitalize on the growing demand for diagnostic solutions, targeting revenue growth of 15-20% annually in the Diagnostics segment.
How Enzo Biochem, Inc. (ENZ) Makes Money
Business Segments
Enzo Biochem, Inc. generates revenue through several key business segments:
- Clinical Labs: Revenue primarily from diagnostic testing services.
- Life Sciences: Sales of products and services to research institutions.
- Pharmaceuticals: Development and commercialization of therapeutics.
Revenue Breakdown
For fiscal year 2023, Enzo Biochem reported total revenues of approximately $25.8 million.
| Segment | Revenue (in million USD) | Percentage of Total Revenue |
|---|---|---|
| Clinical Labs | $15.6 | 60.5% |
| Life Sciences | $8.5 | 32.9% |
| Pharmaceuticals | $1.7 | 6.6% |
Clinical Laboratories
The Clinical Labs segment includes comprehensive diagnostic testing services with a focus on molecular diagnostics. In 2023, the segment saw a revenue increase of 18% compared to the previous year.
Life Sciences Division
This segment is focused on providing research products, including reagents and assay services. Life Sciences revenue increased by 12% year-over-year, driven by a growing demand for genomic and proteomic analysis tools.
Pharmaceutical Development
Enzo Biochem is also involved in the development of biopharmaceuticals. The company reported expenses related to R&D expenses in the pharmaceuticals segment of approximately $4.1 million for FY 2023.
Operating Expenses
Operating expenses for Enzo Biochem in 2023 were reported at $28.4 million, which includes:
- Research and Development: $4.1 million
- Sales and Marketing: $6.5 million
- General and Administrative: $17.8 million
Net Income
For FY 2023, Enzo Biochem, Inc. reported a net loss of approximately $3.7 million, compared to a net income of $1 million in FY 2022.
Cash Flow
The company's cash and cash equivalents at the end of 2023 were reported to be $5.3 million. The cash used in operating activities was $7.8 million.
Market Position
As of October 2023, Enzo Biochem has a market capitalization of approximately $55 million.
Strategic Partnerships
The company has formed various strategic partnerships to bolster its revenue streams. Collaborations with healthcare systems and academic institutions have facilitated an increase in service contracts and research funding.
Future Outlook
The management of Enzo Biochem anticipates revenue growth driven by expanding its Clinical Lab services and increasing demand in the Life Sciences segment, with a target to achieve $30 million in total revenue by the end of fiscal 2024.
Enzo Biochem, Inc. (ENZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support